KYORIN has been granted a patent for a compound with antiviral properties against picornavirus genus, specifically rhinovirus. The compound is represented by Formula (1) in the patent. GlobalData’s report on KYORIN gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on KYORIN, was a key innovation area identified from patents. KYORIN's grant share as of April 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11952387B2) discloses a compound represented by Formula (1) and its various derivatives, including pharmacologically acceptable salts and hydrates. The compound is designed to target viruses belonging to the family Picornaviridae, such as enteroviruses, rhinoviruses, and coxsackieviruses. The patent claims cover a wide range of structural variations within the compound, allowing for flexibility in formulation and application.
Moreover, the patent claims encompass the use of the compound in pharmaceutical compositions for treating viral infections caused by the specified viruses, as well as for preventing exacerbation of conditions like asthma or COPD. The compound's mechanism of action makes it a promising candidate for antiviral therapy and respiratory disease management. The patent's comprehensive coverage of the compound's derivatives and therapeutic applications highlights its potential for addressing unmet medical needs in these areas.
To know more about GlobalData’s detailed insights on KYORIN, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.